and J.S.C.) and grant RRG 715234 from the Muscular Dystrophy Association (to J.S.C.). Author Contributions Conceptualization, N.E.B., S.D.H., and J.S.C.; Methodology, N.E.B., H.T., S.D.H., and J.S.C.; Investigation, N.E.B. muscle types. These results suggest that the high rate of necrosis and regeneration in skeletal muscles, compared with the relative stability of dystrophic cardiomyocytes, caused the rapid loss of edited genomes. Consequently, stable dystrophin expression in DMD skeletal muscles will require either highly efficient gene editing or the use of cotreatments that decrease skeletal muscle Gilteritinib hemifumarate degeneration. mice display a uniquely accelerated pace of turnover during an early crisis period that occurs between 3 and 7?weeks postnatally.19 This provides an opportunity for conducting stringent tests Mouse monoclonal to AURKA of AAV-mediated dystrophin gene correction and of the resulting gene-edited dystrophins during a period of high skeletal muscle turnover. Here, we present results describing dystrophin gene correction via deletion of exons 52 and 53 following AAV-mediated delivery of CRISPR-Cas9 to 2- and 11-week-old dystrophic (gene editing. In contrast, stable editing and dystrophin expression are observed in cardiac muscles without codelivery of Dys, reflecting the paucity of cardiomyocyte loss. These results indicate that a functional long-term therapy for DMD using CRISPR-Cas9 will require highly efficient skeletal muscle gene editing and that such an approach could benefit greatly from complimentary approaches that stabilize myofibers to prevent loss of vector and corrected genomes. However, life-long therapies will also require genomic correction of muscle SCs (or satellite cells),20 since even normal myofibers exhibit gradual myonuclear turnover throughout life. Results CRISPR-Cas9 Correction of Dystrophin in (SaCas9) using the creatine kinase (CK)8e MSEC, and a separate target vector contained two U6 promoter-driven sgRNA cassettes designed to target introns 51 and 53 so as to excise a 45-kb region, including exons 52-53 (Figure?1). To facilitate detection of successful Gilteritinib hemifumarate transduction, a cytomegalovirus (CMV)-mCherry reporter gene Gilteritinib hemifumarate was also included in the target vector (Figure?1). Four different doses and ratios of nuclease to sgRNA vgs were tested following systemic administration into young-adult (11-week-old) gene in striated muscle. Upon excision of the 45-kb intervening genomic region that contains the C to T nucleotide substitution in exon 53 of gene editing (Figures 3A and 3B; Table 1).13 Whereas all doses and ratios resulted in successful 5253 gene editing in the hearts, quantification via digital PCR (dPCR) showed that the high dose of 1 1? 1013/1? 1013 vg led to the highest 5253-correction efficiency (~1.9% of total genomes; Figure?3C, top; Table 1 [12-week data]). Since cardiomyocytes contribute only about 30%C35% of the total cellular genomes in rat cardiac muscle,21 this suggests that less than 6% of the cardiomyocytes exhibit corrected genomes 3?months after treatment (see Gilteritinib hemifumarate Discussion). The highest dose also exhibited significantly elevated yet strikingly low overall levels of 5253 correction in skeletal muscles (~0.14% [diaphragm] and 0.22% [gastrocnemius] versus the other tested doses [Figure?3C, bottom; Table 1 (12-week data)]). Thus, even after correcting for nonmyonuclear genomes, less than 1% of myofiber dystrophin genes was corrected under these conditions. Open in a separate window Figure?3 Systemic Dystrophin Correction Is Enhanced with Increased Vector Dose and Demonstrates Preferred Dependence on Target versus Nuclease Vector Availability Comparison of dose and ratio of muscle-specific nuclease and target vectors (Figure?1A) at 12?weeks following systemic delivery into young-adult (11-week-old skeletal muscles, which starts around 3?weeks of age.19 A separate cohort of age-matched mice was injected with 5? 1012 vg of rAAV6 vectors expressing Dys 5 (Dys5 or Dys) under control of the CK8e RC to serve as a reference, since robust Dys expression has been shown to persist through this crisis phase and much longer.7,22 Endpoint analyses at 4 (n?= 2) or 18 (n?= 5) weeks post-treatment demonstrated significant expression of the mCherry reporter (Figure?1) in the hearts of treated mice at both time points (Figure?4A). Conversely, whereas mCherry expression was weak but detectable in skeletal muscles at week 4 post-treatment, by week 18, the signal was greatly reduced (Figure?4A, top), suggesting an almost Gilteritinib hemifumarate complete loss of skeletal muscle fibers that had been transduced by the mCherry-carrying vectors. A similar trend was observed while monitoring expression of 5253-dys in skeletal muscles via immunostaining, where a concomitant decrease in dystrophin-positive myofibers and increase in central nucleation were observed between 4 and 18?weeks post-treatment, suggesting that.